Evidence map›Paper›PMID 39572641›Full record

ArticleNature immunology2025

PD-1 and CD73 on naive CD4

Felix Sebastian Nettersheim, Simon Brunel, Robert S Sinkovits, Sujit Silas Armstrong, Payel Roy, Monica Billitti, Kouji Kobiyama, Ahmad Alimadadi, Sergei Bombin, Lihui Lu and 5 more

Abstract read
In one paragraph

Article in Nature immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Neonatal liver niches program T cell tolerance.bioRxiv : the preprint server for biology · 2026
    Article
  3. Review
  4. Loss of effector TNature cardiovascular research · 2025
    Article
  5. Review
  6. Review
  7. Immune tolerance in peripheral CD4Nature immunology · 2025
    Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Felix Sebastian Nettersheim *La Jolla Institute for Immunology, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-4090-3357
Simon Brunel *La Jolla Institute for Immunology, La Jolla, CA, USA.ORCID http://orcid.org/0000-0001-7908-1840
Robert S Sinkovits *San Diego Supercomputer Center, University of California, La Jolla, CA, USA.ORCID http://orcid.org/0000-0001-7377-9762
Sujit Silas ArmstrongLa Jolla Institute for Immunology, La Jolla, CA, USA.
Payel RoyLa Jolla Institute for Immunology, La Jolla, CA, USA.
Monica BillittiLa Jolla Institute for Immunology, La Jolla, CA, USA.
Kouji KobiyamaLa Jolla Institute for Immunology, La Jolla, CA, USA.
Ahmad AlimadadiLa Jolla Institute for Immunology, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-7888-5019
Sergei BombinImmunology Center of Georgia, Augusta University, Augusta, GA, USA.
Lihui LuLa Jolla Institute for Immunology, La Jolla, CA, USA.
Martina ZocchedduImmunology Center of Georgia, Augusta University, Augusta, GA, USA.
Mohammad OliaeimotlaghImmunology Center of Georgia, Augusta University, Augusta, GA, USA.ORCID http://orcid.org/0000-0002-2333-2556
Chris A BenedictLa Jolla Institute for Immunology, La Jolla, CA, USA.
Alessandro SetteLa Jolla Institute for Immunology, La Jolla, CA, USA.ORCID http://orcid.org/0000-0001-7013-2250
Klaus LeyLa Jolla Institute for Immunology, La Jolla, CA, USA. kley@augusta.edu.ORCID http://orcid.org/0000-0001-9339-3672

Funding

Project 4: APOB-specific CD4 and CD8 T cells exacerbate atherosclerosisP01HL136275 · NHLBI · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI Catherine C Hedrick · 2017 to 2026
$25.5M
Vascular macrophages and T cells in atherosclerosisR35HL145241 · NHLBI · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI LEY, KLAUS F. · 2019 to 2025
$5.9M
The role of TRAIL in immune control of cytomegalovirusR01AI101423 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI BENEDICT, CHRISTOPHER A · 2013 to 2023
$4.6M
CD4 T cell control of cytomegalovirusR01AI139749 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI BENEDICT, CHRISTOPHER A · 2019 to 2023
$3.2M
NovaSeq5000 High Throughput SequencerS10OD025052 · OD · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI SEUMOIS, GREGORY · 2018 to 2018
$832k
FACSAria II Cell SorterS10RR027366 · NCRR · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI CROFT, MICHAEL · 2011 to 2011
$514k
The role of TRAIL in immune control of cytomegalovirusR56AI101423 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI BENEDICT, CHRISTOPHER A · 2012 to 2012
$435k
Deutsche Forschungsgemeinschaft (German Research Foundation) NE 2574/1-1NCRR NIH HHS S10 RR027366NHLBI NIH HHS P01 HL136275NHLBI NIH HHS R35 HL145241NIAID NIH HHS R01 AI101423NIAID NIH HHS R01 AI139749NIAID NIH HHS R56 AI101423NIH HHS S10 OD025052U.S. Department of Health & Human Services | National Institutes of Health (NIH) AI101423U.S. Department of Health & Human Services | National Institutes of Health (NIH) AI139749
6 · The paper itself

Abstract

Vaccination with self- and foreign peptides induces weak and strong expansion of antigen-specific CD4

Indexed as

5'-NucleotidaseCD4-Positive T-LymphocytesMice, Inbred C57BLProgrammed Cell Death 1 ReceptorAnimalsAutoantigensFemaleHistocompatibility Antigens Class IIMiceMice, Knockout5'-NucleotidaseAutoantigensHistocompatibility Antigens Class IIPdcd1 protein, mouseProgrammed Cell Death 1 Receptor

Identifiers

PMID39572641
PMCPMC11697576

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.